library.onepin.app/tirzepatide Peptide Education Library

Education only, not medical advice◆ 21+◆ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Metabolic

Metabolic Dual GLP-1/GIP receptor agonist

Tirzepatide

Mounjaro · Zepbound

Dual GLP-1/GIP receptor agonistFDA-approved (Mounjaro, Zepbound)Long-acting incretin mimeticAnti-obesity medication

Tirzepatide is a dual GLP-1/GIP receptor agonist FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). It produced up to 22.5% body weight loss in the SURMOUNT trials, exceeding semaglutide. The dual agonist mechanism combines appetite suppression (GLP-1) with enhanced insulin sensitivity and lipid metabolism (GIP). Tirzepatide represents the bridge between single-agonist semaglutide and triple-agonist retatrutide.

Quick Start

Route

SubQ injection (weekly)

Start low

2.5 mg weekly, titrating up

Frequency

Once weekly

Timing

No fasting required

Any time of day, with or without food. Once weekly on the same day each week.

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Quick Start

Conservative start

2.5 mg weekly, titrating up · SubQ injection (weekly) · Once weekly

Lowest starting point. Hold about a week to assess tolerance before stepping up.

2.5 mg weekly, titrating up

Once weekly

Standard

Titration Schedule

2.5 -> 5 -> 7.5 -> 10 -> 12.5 -> 15 mg · SubQ · Weekly

human clinical trial · FDA Zepbound label titration

2.5 -> 5 -> 7.5 -> 10 -> 12.5 -> 15 mg

Weekly

Standard

Weight Management (Max Dose)

15 mg · SubQ · Weekly

human clinical trial · SURMOUNT-1 (Jastreboff et al. 2022, NEJM)

15 mg

Weekly

Reconstitution CalculatorU-100

Vial strength

BAC water

Target dose

050100u

Draw to

— units

◆

How it works

Tirzepatide activates both GLP-1 and GIP receptors. GLP-1 activation provides appetite suppression, slowed gastric emptying, and enhanced insulin secretion. GIP activation improves insulin sensitivity, enhances lipid metabolism in adipose tissue, and may improve beta-cell function. The dual mechanism produces superior weight loss and glycemic control compared to GLP-1-only agents.

What to expect

Early

Days 1–7

Weeks 1-4: Appetite suppression during titration.

Mid

Weeks 2–4

Weeks 4-12: Consistent weight loss.

Later

Weeks 4–12

Months 3-12: Significant cumulative results.

Evidence

HumanStrong

AnimalPresent

In-vitroPresent

2022Tirzepatide Once Weekly for the Treatment of Obesity · Jastreboff AM et al, New England Journal of Medicine ↗peer reviewed

2021Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes · Frias JP et al, New England Journal of Medicine ↗peer reviewed

2021Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial · Rosenstock J et al, Lancet ↗peer reviewed

2021Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial · Del Prato S et al, Lancet ↗peer reviewed

The honest take

◆

Superior to semaglutide

SURPASS-2 showed tirzepatide superior to semaglutide 1mg for weight loss and HbA1c reduction. Confirmed.

22.5% weight loss

Supported

Confirmed in SURMOUNT-1 at 15 mg dose.

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

BPC-157BPC GI healing may reduce GLP-1 nausea.

AOD-9604Dual appetite suppression + direct fat metabolism.

Keep separate

ALL (syringe)PIN ALONE. GLP-1 class.

SemaglutideDo not stack GLP-1 agonists.

RetatrutideDo not stack GLP-1 agonists.

MetforminMonitor glucose.

Side effects & safety

Commonly reported

Nausea
Diarrhea
Constipation
Decreased appetite

Less common & notes

Same GLP-1 class warnings: pancreatitis, gallbladder, gastroparesis, thyroid C-cell signal in rodents.
Oral contraceptives may be less reliable during dose initiation and escalation: delayed gastric emptying (GLP-1 / amylin) can reduce oral drug absorption - Tirzepatide carries an FDA label warning to use a backup or non-oral method for 4 weeks after starting and after each dose increase.

Pharmacokinetics

Illustrative plasma concentration · 24 h

Half-life

120h

Peak · Tmax

24h

Elimination

600h

Activity

7 days (supports weekly dosing; appetite suppression and glycemic control sustained between doses)

Storage. Pens: 21 days room temp. Compounded: 28 days 2-8C.

Regulatory status

FDA-approved as Mounjaro and Zepbound. WADA prohibited under S4.

Put it to work

Calculate, log & track

Open Tirzepatide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Tirzepatide in the app →

Go deeper

The guide & community

The complete Tirzepatide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community